down arrow

ABVC BioPharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00091F3047
USD
2.53
-0.02 (-0.78%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.532.60

52 Week

0.405.48
Valuation
Technical
Day's Volume

CASH

47.83 k

Shareholding (Jun 2025)

FII

0.41%

Held by 3 FIIs

DII

97.55%

Held by 2 DIIs

Promoter

0.00%

How big is ABVC BioPharma, Inc.?

22-Jun-2025

As of Jun 18, ABVC BioPharma, Inc. has a market capitalization of 34.02 million, with net sales of 0.51 million and a net profit of -2.21 million over the last four quarters. The company reported shareholder's funds of 1.23 million and total assets of 7.54 million as of Dec 24.

Market Cap: As of Jun 18, ABVC BioPharma, Inc. has a market capitalization of 34.02 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ABVC BioPharma, Inc. reported net sales of 0.51 million and a net profit of -2.21 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.23 million and total assets of 7.54 million.

Read More

What does ABVC BioPharma, Inc. do?

22-Jun-2025

ABVC BioPharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $34.02 million. Key metrics include a debt-to-equity ratio of 0.37 and a return on equity of -41.12%.

Overview: <BR>ABVC BioPharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 34.02 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.37 <BR>Return on Equity: -41.12% <BR>Price to Book: 6.29<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is ABVC BioPharma, Inc. overvalued or undervalued?

25-Jun-2025

As of August 14, 2023, ABVC BioPharma, Inc. is considered overvalued with significant financial concerns, reflected in its high Price to Book Value of 4.85 and negative ratios, despite a strong year-to-date stock performance of 232.20%.

As of 14 August 2023, the valuation grade for ABVC BioPharma, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its high Price to Book Value of 4.85 and negative ratios such as EV to EBITDA at -17.19 and ROE at -41.12%. These figures suggest that the company is struggling to generate returns and is not effectively utilizing its capital.<BR><BR>In comparison to peers, ABVC BioPharma's EV to EBITDA ratio of -21.9563 is notably worse than Tempest Therapeutics, Inc. at -0.2631 and Aptorum Group Ltd. at -2.9175, highlighting its relative underperformance in the sector. The company's recent stock performance has been impressive, with a year-to-date return of 232.20%, significantly outpacing the S&P 500's 2.44% over the same period. However, this does not mitigate the valuation concerns, as the underlying financial metrics indicate that the stock may not be justified at its current price level.

Read More

Is ABVC BioPharma, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, ABVC BioPharma, Inc. shows a mildly bullish trend with strong year-to-date and annual performance, but mixed technical indicators suggest caution moving forward.

As of 29 August 2025, the technical trend for ABVC BioPharma, Inc. has changed from bullish to mildly bullish. The current technical stance is mildly bullish, driven by daily moving averages and weekly Bollinger Bands indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly RSI remains bearish, which adds to the mixed signals. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date and over the past year, with returns of 361.02% and 312.12%, respectively, compared to the S&P 500's 12.22% and 17.14%. However, the longer-term returns over 3 and 5 years show substantial underperformance relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 66 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

-46.80%

stock-summary
Price to Book

9.41

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.64%
0%
-6.64%
6 Months
53.33%
0%
53.33%
1 Year
368.52%
0%
368.52%
2 Years
88.81%
0%
88.81%
3 Years
230.76%
0%
230.76%
4 Years
-91.37%
0%
-91.37%
5 Years
-94.05%
0%
-94.05%

ABVC BioPharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is ABVC BioPharma, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for ABVC BioPharma, Inc. has changed from bullish to mildly bullish. The current technical stance is mildly bullish, driven by daily moving averages and weekly Bollinger Bands indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly RSI remains bearish, which adds to the mixed signals. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date and over the past year, with returns of 361.02% and 312.12%, respectively, compared to the S&P 500's 12.22% and 17.14%. However, the longer-term returns over 3 and 5 years show substantial underperformance relative to the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-3.89%
EBIT Growth (5y)
3.04%
EBIT to Interest (avg)
-6.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.07%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.85
EV to EBIT
-14.43
EV to EBITDA
-17.19
EV to Capital Employed
3.81
EV to Sales
28.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.39%
ROE (Latest)
-41.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (2.04%)

Foreign Institutions

Held by 3 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -155.56% vs -1,000.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-0.60",
          "chgp": "-266.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-0.90",
          "chgp": "-155.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 150.00% vs -80.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.14% vs 49.08% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.20",
          "chgp": "150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-6.40",
          "chgp": "29.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "1.30",
          "chgp": "-38.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.30",
          "val2": "-8.30",
          "chgp": "36.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,233.40%",
          "val2": "-44,392.40%",
          "chgp": "3,515.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.20
-0.60
-266.67%
Interest
0.10
0.20
-50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.30
-0.90
-155.56%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -155.56% vs -1,000.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.50
0.20
150.00%
Operating Profit (PBDIT) excl Other Income
-4.50
-6.40
29.69%
Interest
0.80
1.30
-38.46%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.30
-8.30
36.14%
Operating Profit Margin (Excl OI)
-9,233.40%
-44,392.40%
3,515.90%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 150.00% vs -80.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.14% vs 49.08% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About ABVC BioPharma, Inc. stock-summary
stock-summary
ABVC BioPharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."